 Ifosfamide
"Ifosfamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
| Descriptor ID |
D007069
|
| MeSH Number(s) |
D02.455.526.728.650.730.243.250 D02.705.672.500.243.250 D03.383.533.500
|
| Concept/Terms |
Ifosfamide- Ifosfamide
- Isophosphamide
- Isofosfamide
- Iphosphamide
- Iso-Endoxan
- Iso Endoxan
NSC-109,724- NSC-109,724
- NSC 109,724
- NSC109,724
- NSC-109724
- NSC 109724
- NSC109724
|
Below are MeSH descriptors whose meaning is more general than "Ifosfamide".
Below are MeSH descriptors whose meaning is more specific than "Ifosfamide".
This graph shows the total number of publications written about "Ifosfamide" by people in UAMS Profiles by year, and whether "Ifosfamide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ifosfamide" by people in Profiles over the past ten years.
-
Douglass DP, Coffin CM, Randall RL, Yang Y, Barkauskas DA, Million L, McCarville MB, Pappo AS, Weiss AR, Spunt SL. Clinical features and outcomes of young patients with low-grade non-rhabdomyosarcoma soft tissue sarcomas treated with a risk-based strategy: A report from Children's Oncology Group study ARST0332. Pediatr Blood Cancer. 2024 Aug; 71(8):e31062.
-
Khandelwal P, Govindarajan S, Bagga A. Management and outcomes in children with lupus nephritis in the developing countries. Pediatr Nephrol. 2023 04; 38(4):987-1000.
-
Mascarenhas L, Ogawa C, Laetsch TW, Weigel BJ, Bishop MW, Krystal J, Borinstein SC, Slotkin EK, Muscal JA, Hingorani P, Levy DE, Mo G, Shahir A, Wright J, DuBois SG. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Med. 2021 02; 10(3):843-856.
-
Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, Ramos JC, Sparano J, Ambinder RF, Lee J, Cesarman E, Yahyaei S, Mitsuyasu R, Wachsman W. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood Adv. 2018 12 26; 2(24):3618-3626.
-
Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 09; 126(2):160-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|